“…Both karrikins and SLs act through the F‐box protein MAX2 (MORE AXILLARY BRANCHES2), which targets members of the SMXL (SUPPRESSOR‐OF‐MAX2‐1‐LIKE) family of repressor proteins for polyubiquitination and subsequent proteasomal degradation (Nelson et al., 2011; Stanga et al., 2013; Zhou et al., 2013; Jiang et al., 2013; Zhao et al., 2015). Specificity in karrikin and SL response arises both from intrinsic differences in ligand preference between KAI2 and D14 (Scaffidi et al., 2014; Wang et al., 2020; Arellano‐Saab et al., 2021; Yao et al., 2021), and through degradation of specific SMXL proteins that associate with each receptor upon ligand recognition (Soundappan et al., 2015; Wang et al., 2015, 2020; de Saint Germain et al., 2016; Khosla et al., 2020; Zheng et al., 2020). The similar componentry of KAI2‐ and D14‐dependent signalling, the evolutionary conservation of KAI2, and the fact that kai2 phenotypes are opposite to the effects of applying karrikins, collectively have led to the proposal that KAI2 is a receptor for an endogenous butenolide compound(s) called ‘KAI2 ligand’ (KL; Nelson et al., 2011; Conn and Nelson, 2016; Sun et al., 2016; Yao et al., 2021).…”